Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that psoriasis prevalence among transgender individuals is similar to that in the general population, with possible links to gender-affirming hormone therapy needing more research.

Transgender women on estrogen therapy can develop melasma and need proper skin care.

Masculinizing hormone therapy increases the risk of hair loss in transgender and gender-diverse patients.

This study reviewed literature on dermatological changes in transgender and gender diverse individuals during gender affirming medical transition, identifying risks like acne and hypertrophic scars, and provided tailored care recommendations for health professionals.

In this study, proteolytic enzymes applied to mice skin caused severe degeneration in hair follicles, including detachment of stem cells from their niche, suggesting potential impairment of stem cell function.

This study found that gender-affirming hormone therapy in transgender men increased acne and male pattern hair loss, while in transgender women, it led to melasma and female pattern hair loss.

Spironolactone and finasteride are equally effective for hirsutism in transgender women.

In this study, sublingual minoxidil was found to be a safe and effective treatment for increasing hair growth in transgender individuals with mild androgenetic alopecia who are undergoing full-dose testosterone therapy.

This paper argues that androgenetic alopecia in transgender and gender-diverse individuals is clinically significant, suggesting individualized and gender-affirming treatment approaches, with oral minoxidil as a key therapy.

Facial aesthetic procedures improve quality of life for transgender individuals.

Transgender women have similar fitness to cisgender women, while transgender men have higher fat and lower strength than cisgender men; hormone therapy affects body composition and strength.

Sublingual minoxidil significantly improves hair growth in transgender individuals on testosterone therapy.

Oral minoxidil can effectively treat hair loss in transgender and gender-diverse individuals.

Transgender and gender-diverse teens need specialized skin and mental health care.

This commentary highlights that transgender patients are often dissatisfied with standard hormone replacement therapy for hair-related goals, emphasizing the need for dermatologists to provide informed guidance and tailor treatments.

This review reports that transgender patients undergoing hormone therapy may experience acne differently, necessitating tailored treatments that take into account skin dryness and the potential need for maintenance topical treatments.

This study aims to evaluate the prevalence of androgenetic alopecia in transgender men undergoing testosterone therapy, noting that such hormone treatment can lead to dermatological issues that significantly affect their quality of life. Results are not reported in the abstract.

This article highlights the gap between medically necessary dermatologic gender-affirming procedures and insurance coverage for transgender and gender diverse service members in the US Military, and discusses how dermatologists can support gender-affirming care and address existing healthcare disparities.

This study found that topical minoxidil significantly enhanced facial hair growth in transgender individuals assigned female at birth undergoing gender affirming hormone therapy, with improvements most notable after six months of use.

In this study, researchers reported that transgender men undergoing testosterone therapy experienced varying rates of alopecia (hair loss), which may be influenced by the duration of treatment, genetic factors, and family history.

This document serves as a resource for pediatricians and primary care providers to guide gender-affirming health care for transgender and gender-diverse youth, including potential medical transition options.

This article discusses the incidence of androgenetic alopecia in transgender and gender diverse patients undergoing gender affirming hormone therapy but presents no new clinical findings, highlighting a gap in large-scale studies.

This article discusses the role of dermatopathologists in addressing healthcare inequities faced by transgender patients and reports no new clinical findings; it emphasizes the importance of accurate data management to prevent misdiagnosis and insurance issues.

This paper reviews hair restoration surgery options for transgender patients and reports no new clinical results; the authors emphasize tailoring treatment plans to individual facial features and hair characteristics.

This abstract lacks findings or results and does not provide a summary about any specific research study or topic.

This review discusses transgender healthcare needs in gynecology, including creating a welcoming clinic environment and understanding treatments, but it reports no new clinical findings.

This study found that transgenic expression of Endothelin 3 in mice can maintain a dark pigmentation phenotype independently of Mc1r signaling by regulating melanogenic genes.

This study concluded that transgenic somatic cell nuclear transfer technology can produce cashmere goat blastocysts carrying the K2.9 gene using specific fibroblast cells and activation methods.

This study successfully established a transgenic sheep fibroblast cell line expressing the spider dragline silk protein gene, laying groundwork for developing transgenic sheep with this capability in hair follicles.

EGF affects hair and skin development.